$MRNA, $ALNY, $GMAB, $BGNE, $ROIV, $HALO, and $PCVX: Biotech sector stocks that have fallen by over 10% in the past month.
Some biotech sector stocks have experienced more significant declines in the past month compared to the overall market, with drops exceeding 10%. For quick trade insights, you can subscribe to our robots at Swing-Trader-High-Volatility-Stocks-for-Active-Trading-TA-FA.
The group's average market capitalization is $21.3 billion, ranging from $7.9 billion (ROIV) to $37.4 billion (MRNA).
In terms of price performance, the average weekly change was -4.48%, monthly change was -12.29%, and quarterly change was -13.57%. Notably, BGNE had the highest weekly price growth at 2.82%, while GMAB experienced the largest decline at -8.22%.
Regarding trading volume, the group had an average weekly volume growth of 19.56%. Monthly volume growth averaged 22.22%, and quarterly volume growth averaged 48.52%.
In terms of fundamental analysis ratings (scale: 1 to 100, with 1 being the best and 100 being the worst):
- Valuation Rating: 74
- P/E Growth Rating: 76
- Price Growth Rating: 65
- SMR Rating: 77
- Profit Risk Rating: 70
The Seasonality Score is 25 on a scale of -100 to +100.
MRNA's Stochastic Oscillator exited the overbought zone on October 12, 2023, signaling a potential bearish trend with a 90% likelihood of a decline.
- MRNA Current price: $98.30; trading between $175.56 resistance and $69.57 support lines. It experienced a -9% Downtrend in the month of 09/13/23 - 10/13/23, with a -5% weekly fall.
GMAB's MACD Histogram turned negative on October 12, 2023, suggesting a potential stock decline with a 69% probability.
- GMAB Current price: $32.28; below the $33.91 lowest support line. It faced an -11% Downtrend in the month of 09/13/23 - 10/13/23, dropping -8% weekly.
BGNE's RSI Oscillator exited the oversold zone on October 05, 2023, indicating a potential shift from a downtrend to an uptrend with an 82% probability.
- BGNE Current price: $178.79; below the $239.67 lowest resistance line. It experienced an -11% Downtrend in the month of 09/13/23 - 10/13/23, but showed a +3% Uptrend in the week of 10/06/23 - 10/13/23.
ROIV's RSI Oscillator moved out of the overbought zone on September 28, 2023, hinting at a possible shift from an uptrend to a downtrend with a 78% chance of a decline.
- ROIV Current price: $10.08; above the $8.59 highest resistance line. It faced a -10% Downtrend during the month of 09/13/23 - 10/13/23 and declined -7% weekly.
HALO's Momentum Indicator turned negative on September 26, 2023, suggesting a new potential downward trend with a 69% likelihood.
- HALO Current price: $36.55; below the $39.43 lowest support line. It experienced an -11% Downtrend during the month of 09/13/23 - 10/13/23 and fell -2% weekly.
PCVX's Stochastic Oscillator has been in the oversold zone for 1 day, indicating a potential upcoming price bounce.
- PCVX Current price: $46.00; trading between $61.37 resistance and $23.75 support lines. It experienced an -11% Downtrend during the month of 09/13/23 - 10/13/23 and declined -6% weekly.
HALO in upward trend: price expected to rise as it breaks its lower Bollinger Band on December 18, 2024
HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where HALO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HALO's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on December 04, 2024. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on December 18, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
HALO moved below its 50-day moving average on November 14, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HALO crossed bearishly below the 50-day moving average on November 19, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.193) is normal, around the industry mean (14.556). P/E Ratio (15.550) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). HALO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (6.439) is also within normal values, averaging (256.215).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology